在远距离和中等血管阻塞中风的个性化治疗使用验证的可解释的反事实性治疗估计模型
Mohamed F Doheim1, Mahmoud H Mohammaden2,3, Hend Abdelhamid4
1Departments of Neurology and Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Annals of neurology
|January 28, 2026
概括
一个新的工具,距离和中血管阻塞中风 (DUSK) 工具,帮助医生个性化治疗DMVO中风患者. 它确定了最有可能受益于内血管治疗 (EVT) 而不是医疗管理 (MM) 的个人.
科学领域:
- 神经学 神经学
- 医疗信息学 医疗信息学
- 生物统计学 生物统计学
背景情况:
- 远端中血管阻塞 (DMVO) 中风的最佳治疗方法尚不清楚,仅有有限的证据比较内血管治疗 (EVT) 和医疗管理 (MM).
- 个性化治疗效益评估对于优化中风护理结果至关重要.
研究的目的:
- 开发和验证一个预测建模工具,用于评估DMVO中风的个体治疗益处.
- 用可解释的反事实治疗估计来进行个性化治疗决策.
主要方法:
- 从7个中风中心对321名患有DMVO中风的成年患者进行了回顾性分析.
- 开发一个处罚后勤回归 (弹性网) 模型来估计有利的结果概率 (90天的mRS 0-2).
- 模型的内部和外部验证使用交叉验证,引导和独立队列 (n=86).
主要成果:
- 在EVT和MM之间,在有利的结果,死亡率或症状出血方面没有显著的整体群体差异.
- 预测模型在治疗效果中发现了显著的异质性,EVT的益处因NIHSS得分和治疗延迟而异.
- 强大的内部 (AUC=0.77) 和外部 (AUC=0.74) 验证证明了该模型的性能和通用性.
结论:
- 经过验证的远距离和中血管阻塞中风 (DUSK) 工具可以对DMVO中风中EVT益处进行个性化估计.
- 这种可解释的框架支持精准医学,通过确定患者子组,他们最有可能从EVT中受益,而不是MM.
- DUSK工具有助于优化DMVO中风的治疗策略,朝着个性化患者护理迈进.
相关概念视频
Counterfactual Thinking
238
Counterfactual thinking is a cognitive process wherein individuals mentally reconstruct alternative versions of past events, often beginning with “what if” or “if only.” This reflective mechanism plays a significant role in shaping emotional experiences and guiding future behavior. Though typically triggered by unfavorable or unexpected outcomes, counterfactual thinking can also emerge in mundane, everyday decisions and experiences, revealing its deep entrenchment in...
238
Open Angle Glaucoma: Treatment
990
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
990
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Parkinson's Disease: Treatment
1.1K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.1K
Alzheimer's Disease: Treatment
914
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
914
Anticholinesterase Agents: Poisoning and Treatment
1.6K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K


